Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

RVTY

Revvity Inc.

Apr 26 • 04:00PM ET

101.51

Dollar change -0.58
Percentage change -0.57	%

Healthcare • Diagnostics & Research • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO IVV VTV RSP VOE VHT IWR IWD

Scroll to Statements

Index	S&P 500	P/E	17.82	EPS (ttm)	5.70	Insider Own	0.39%	Shs Outstand	123.43M	Perf Week	0.64%
Market Cap	12.54B	Forward P/E	19.56	EPS next Y	5.19	Insider Trans	-9.67%	Shs Float	123.05M	Perf Month	-3.70%
Income	717.31M	PEG	2.10	EPS next Q	0.94	Inst Own	87.92%	Short Float	2.93%	Perf Quarter	-7.72%
Sales	2.75B	P/S	4.56	EPS this Y	0.02%	Inst Trans	-9.87%	Short Ratio	4.11	Perf Half Y	1.83%
Book/sh	63.79	P/B	1.59	EPS next Y	11.57%	ROA	1.30%	Short Interest	3.60M	Perf Year	-21.70%
Cash/sh	12.99	P/C	7.82	EPS next 5Y	8.47%	ROE	2.35%	52W Range	79.50 - 132.54	Perf YTD	-7.14%
Dividend Est.	0.28 (0.27%)	P/FCF	1266.62	EPS past 5Y	-	ROI	6.41%	52W High	-23.41%	Beta	1.09
Dividend TTM	0.28 (0.28%)	Quick Ratio	1.77	Sales past 5Y	1.15%	Gross Margin	52.72%	52W Low	27.69%	ATR (14)	2.55
Dividend Ex-Date	Apr 18, 2024	Current Ratio	2.07	EPS Y/Y TTM	27.71%	Oper. Margin	14.52%	RSI (14)	44.85	Volatility	2.11% 2.39%
Employees	11500	Debt/Eq	0.52	Sales Y/Y TTM	-30.22%	Profit Margin	26.08%	Recom	2.06	Target Price	120.20
Option/Short	Yes / Yes	LT Debt/Eq	0.42	EPS Q/Q	-23.54%	Payout	-	Rel Volume	0.94	Prev Close	102.09
Sales Surprise	2.80%	EPS Surprise	7.32%	Sales Q/Q	-6.11%	Earnings	Apr 29 BMO	Avg Volume	876.74K	Price	101.51
SMA20	-1.74%	SMA50	-3.03%	SMA200	-4.37%	Trades		Volume	820,246	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-16-24	Downgrade	UBS	Buy → Neutral	$105 → $125
Jan-04-24	Upgrade	Evercore ISI	In-line → Outperform	$88 → $125
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$95
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Sep-28-23	Initiated	Bernstein	Outperform	$133
Jul-19-23	Initiated	Raymond James	Outperform	$145
May-23-23	Resumed	Goldman	Buy	$150

Apr-25-24 04:15PM	Revvity Board Declares Quarterly Dividend (Business Wire)
12:50PM	Revvity's (RVTY) New Launch to Boost Tuberculosis Testing (Zacks)
08:00AM	Revvity to Present at BofA Securities 2024 Health Care Conference (Business Wire)
Apr-24-24 06:00AM	Revvity Unveils a New Era of Automated Tuberculosis Testing (Business Wire)
Apr-16-24 12:30PM	Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up (Zacks)
06:00AM	Loading…
Apr-15-24 06:00AM	Revvity Signals Software's New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners (Business Wire)
Apr-10-24 10:03AM	Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar? (Zacks)
Apr-04-24 08:00AM	Revvity To Hold Earnings Call on Monday, April 29, 2024 (Business Wire)
Apr-02-24 06:00AM	Preliminary Injunction Granted to Enforce Revvity's Rights and Cloud Software Group's Obligations Related to Spotfire Software (Business Wire)
Apr-01-24 01:04PM	Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio (Zacks)
Mar-21-24 09:39AM	Revvity's (RVTY) New Launch to Boost Research Productivity (Zacks)
Mar-20-24 05:00PM	Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group (Business Wire)
Mar-18-24 11:34AM	Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research (Zacks)
06:00AM	Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication (Business Wire)
Mar-06-24 06:30AM	Moderna Looks to Pare R&D Spending Even as It Pivots From Covid Vaccines (The Wall Street Journal)
05:04PM	Loading…
Feb-29-24 05:04PM	Analyst Report: Revvity, Inc. (Morningstar Research)
Feb-28-24 12:03AM	Decoding Revvity Inc (RVTY): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Feb-14-24 04:55PM	Analyst Report: Revvity, Inc. (Morningstar Research)
Feb-12-24 04:05PM	Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions (Business Wire)
Feb-02-24 09:52AM	Revvity, Inc. (NYSE:RVTY) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-01-24 10:47PM	Q4 2023 Revvity Inc Earnings Call (Thomson Reuters StreetEvents)
01:46PM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:41AM	Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation (Zacks)
09:30AM	Compared to Estimates, Revvity (RVTY) Q4 Earnings: A Look at Key Metrics (Zacks)
07:30AM	Revvity sees 2024 sales, profit above estimates (Reuters)
06:25AM	Revvity: Q4 Earnings Snapshot (Associated Press Finance)
06:22AM	Revvity Initiates 2024 Guidance - Quick Facts (RTT News)
06:00AM	Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023 (Business Wire)
Jan-25-24 04:15PM	Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors (Business Wire)
04:15PM	Loading…
04:15PM	Revvity Board Declares Quarterly Dividend (Business Wire)
10:19AM	Revvity (RVTY) to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-09-24 08:00AM	Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance (Business Wire)
Dec-19-23 08:00AM	Revvity to Present at J.P. Morgan Healthcare Conference (Business Wire)
Dec-01-23 07:47AM	Revvity (RVTY) Launches New Molecular Testing for Newborns (Zacks)
Nov-14-23 08:00AM	Revvity to Present at Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-23 09:02AM	Revvity, Inc. (NYSE:RVTY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 08:54AM	Company News for Oct 31, 2023 (Zacks)
Oct-30-23 10:35PM	Q3 2023 Revvity Inc Earnings Call (Thomson Reuters StreetEvents) -16.13%
05:12PM	Why Revvity Stock Plunged Today (Motley Fool)
01:45PM	Analyst Report: Revvity, Inc. (Morningstar Research)
01:02PM	Markets Rise at Midday Ahead of Key Earnings News, Fed Meeting, and Jobs Data (Investopedia)
12:07PM	Western Digital, Lumentum rise; ON Semiconductor, Revvity fall, Monday, 10/30/2023 (Associated Press Finance)
11:55AM	Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View (Zacks)
11:22AM	UPDATE 1-Revvity says demand to stay weak on biotech funding woes (Reuters)
10:58AM	Revvity Stock Tumbles 18% as Demand From Pharma and Biotech Customers Falls (Barrons.com)
09:30AM	Compared to Estimates, Revvity (RVTY) Q3 Earnings: A Look at Key Metrics (Zacks)
07:50AM	Revvity cuts annual forecast on weak demand for diagnostics, contract research (Reuters)
07:32AM	Revvity Inc (RVTY) Reports Q3 2023 Earnings: A Detailed Review (GuruFocus.com)
07:15AM	Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates (Zacks)
06:10AM	Revvity: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Third Quarter of 2023 (Business Wire)
Oct-26-23 04:15PM	Revvity Board Declares Quarterly Dividend (Business Wire)
10:07AM	Revvity (RVTY) to Report Q3 Earnings: What's in the Cards? (Zacks)
08:00AM	Revvity Debuts Inaugural ESG Report (Business Wire)
Oct-25-23 10:02AM	Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-23 10:00AM	Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-19-23 11:19AM	Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow (Zacks)
Oct-09-23 08:00AM	Revvity To Hold Earnings Call on Monday, October 30, 2023 (Business Wire)
Oct-02-23 10:10AM	Revvity's (RVTY) New Launch to Widen Access to Editing Technology (Zacks)
Sep-26-23 08:34AM	Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure (Business Wire)
Sep-08-23 07:10PM	Analyst Report: Revvity, Inc. (Morningstar Research)
Sep-06-23 12:34PM	Revvity (RVTY)'s True Worth: A Comprehensive Analysis of Its Market Value (GuruFocus.com)
09:36AM	Revvity (RVTY) Launches Three New Preclinical Research Systems (Zacks)
Sep-05-23 08:01AM	Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries (Business Wire)
Aug-31-23 11:31AM	Revvity (RVTY) Down 4.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-23-23 09:00AM	Revvity to Present at Upcoming September Investor Conferences (Business Wire)
Aug-02-23 09:00AM	Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View (Zacks)
Aug-01-23 11:34PM	Q2 2023 Revvity Inc Earnings Call (Thomson Reuters StreetEvents)
09:30AM	Compared to Estimates, Revvity (RVTY) Q2 Earnings: A Look at Key Metrics (Zacks)
07:15AM	Revvity (RVTY) Q2 Earnings and Revenues Top Estimates (Zacks)
06:17AM	Revvity: Q2 Earnings Snapshot (AP Finance)
06:00AM	Revvity Announces Financial Results for the Second Quarter of 2023 (Business Wire)
Jul-31-23 08:40AM	Revvity (RVTY) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-21-23 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
Jul-20-23 08:00AM	Revvity Accelerates NGS Library Prep with Introduction of New Fontus Automated Liquid Handling Workstation at 2023 AACC (Business Wire)
Jul-12-23 08:00AM	Revvity to Hold Earnings Call on Tuesday, August 1, 2023 (Business Wire)
Jun-29-23 08:00AM	Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research (Business Wire)
Jun-21-23 08:00PM	RVTY: Lowering target price to $121.00 (Argus Research)
Jun-12-23 08:00AM	Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development (Business Wire)
Jun-06-23 12:37PM	Revvity (RVTY) Launches New System for Autoimmune Diagnostics (Zacks)
Jun-01-23 09:00AM	Revvitys EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System (Business Wire)
May-24-23 08:00AM	Revvity to Present at Goldman Sachs Global Healthcare Conference (Business Wire)
May-22-23 04:09PM	Analyst Report: Revvity, Inc. (Morningstar Research)
May-19-23 11:41AM	PerkinElmer Completes Transformation to Become Revvity (GuruFocus.com)
May-18-23 06:00AM	Revvity Announces New License Agreement for Next-Generation Base Editing Technology (Business Wire)

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MICHAS ALEXIS P	Director	Feb 29 '24	Sale	109.98	5,000	549,900	55,604	Mar 01 04:05 PM
Vohra Tajinder S	Please See Remarks	Feb 27 '24	Option Exercise	54.56	7,918	432,046	34,031	Feb 29 04:05 PM
Vohra Tajinder S	Please See Remarks	Feb 27 '24	Sale	105.39	7,918	834,441	26,113	Feb 29 04:05 PM
Singh Prahlad R.	Please See Remarks	Feb 23 '24	Sale	105.13	1,144	120,269	102,270	Feb 26 04:05 PM
Goldberg Joel S	Please See Remarks	Feb 23 '24	Sale	105.13	835	87,784	40,900	Feb 26 04:05 PM
Singh Prahlad R.	Please See Remarks	Feb 05 '24	Option Exercise	76.83	57,039	4,382,283	118,838	Feb 07 06:48 PM
Goldberg Joel S	Please See Remarks	Feb 05 '24	Option Exercise	64.18	28,907	1,855,347	53,500	Feb 07 05:50 PM
Vohra Tajinder S	Please See Remarks	Feb 05 '24	Option Exercise	105.62	3,554	375,373	27,359	Feb 07 04:05 PM
Tereau Daniel R	Please See Remarks	Feb 05 '24	Option Exercise	105.62	2,835	299,433	14,446	Feb 07 04:05 PM
Victor Miriame	Please See Remarks	Feb 05 '24	Option Exercise	105.62	2,408	254,333	11,500	Feb 07 06:10 PM
Singh Prahlad R.	Please See Remarks	Feb 05 '24	Sale	104.28	21,217	2,212,480	92,801	Feb 07 06:48 PM
Goldberg Joel S	Please See Remarks	Feb 05 '24	Sale	104.28	15,475	1,613,696	38,025	Feb 07 05:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVTY

Revvity Inc.

Upgrade your FINVIZ experience